Female-to-male (FTM) transgender Gender identity disorder, gender dysphoria
Conditions
Interventions
Finasteride 0.2 mg are orally administered once daily for 3 months. If patients are able to received the drug safely after 3 months, the dosage is increased to 1.0 mg and they are observed for an addi
Sponsors
Tominaga Yusuke
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Patients diagnosed with female-to-male (FTM) transgender who are 20 years of age or older and younger than 60 years at the time of obtaining consent (2) Receiving testosterone replacement therapy in our department. (3) Have androgenetic alopecia (II or higher in the Modified Norwood-Hamilton Classification) (4) Provide sufficient informed consent to participate in the study, and get his or her voluntary written consent.
Exclusion criteria
Exclusion criteria: (1) History of allergy, which is associated with finasteride. (2) Liver dysfunction. (3) Post-sex reassignment surgery. (4) Severe mental disorders (e.g., severe depression). (5) Inappropriate for enrollement decided by the attending physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment-related adverse events at 1 week, 1 month, and 3 months from the start of administration, and percentage of patients who could continue treatment at 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Treatment effect (evaluation of improvement from baseline using photographs of the parietal area using the Norwood-Hamilton classification) (2) Blood examination (CBC, AST, ALT, ALP, gamma- GTP, T-Bil, BUN, Cr, UA, estradiol, testosterone, T.Cho, HDL-C, LDL-C, TG, LH, FSH, D-dimer) (3) Physical examination (weight, BMI, body fat percentage, muscle mass) (4) Subjective symptoms (cessation of menstruation, change in acne) | — |
Contacts
Public ContactYusuke Tominaga
Okayama University Hospital
Outcome results
None listed